Induction of erythroid differentiation and fetal hemoglobin production in human leukemic cells treated with phenylacetate.

There is considerable interest in identifying nontoxic differentiation inducers for the treatment of various malignant and nonmalignant blood disorders, including inborn beta-chain hemoglobinopathies. Using the human leukemic K562 cell line as a model, we explored the efficacy of phenylacetate, an amino acid derivative with a low toxicity index when administered to humans. Treatment of K562 cultures with pharmacologically attainable concentrations of phenylacetate resulted in erythroid differentiation, evident by the reduced growth rate and increased hemoglobin production. The effect was time- and dose- dependent, further augmented by glutamine starvation (phenylacetate is known to deplete circulating glutamine in vivo), and reversible upon cessation of treatment. Molecular analysis showed that phenylacetate induced gamma globin gene expression with subsequent accumulation of the fetal form of hemoglobin (HbF). Interestingly, the addition of phenylacetate to antitumor agents of clinical interest, eg, hydroxyurea and 5-azacytidine, caused superinduction of HbF biosynthesis. The results suggest that phenylacetate, used alone or in combination with other drugs, might offer a safe and effective new approach to treatment of some hematopoietic neoplasms and severe hemoglobinopathies.

[1]  T. Ley,et al.  5-azacytidine selectively increases gamma-globin synthesis in a patient with beta+ thalassemia. , 1982, The New England journal of medicine.

[2]  O. Simell,et al.  Waste Nitrogen Excretion Via Amino Acid Acylation: Benzoate and Phenylacetate in Lysinuric Protein Intolerance , 1986, Pediatric Research.

[3]  C. Mendenhall,et al.  A new therapy for portal systemic encephalopathy. , 1986, The American journal of gastroenterology.

[4]  M. Goldberg,et al.  Treatment of sickle cell anemia with hydroxyurea and erythropoietin. , 1990, The New England journal of medicine.

[5]  G. Stamatoyannopoulos,et al.  Induction of fetal hemoglobin by cell-cycle-specific drugs and recombinant erythropoietin. , 1990, The American journal of pediatric hematology/oncology.

[6]  A. Schechter,et al.  Hematologic responses of patients with sickle cell disease to treatment with hydroxyurea. , 1990, The New England journal of medicine.

[7]  P. Jeannesson,et al.  Induction of erythroid differentiation in human leukemic K-562 cells by membrane-directed action of adriamycin covalently bound to microspheres. , 1990, Cancer research.

[8]  S. Shack,et al.  Phenylacetate: a novel nontoxic inducer of tumor cell differentiation. , 1992, Cancer research.

[9]  C. Lozzio,et al.  Human chronic myelogenous leukemia cell-line with positive Philadelphia chromosome. , 1975, Blood.

[10]  S. Brusilow,et al.  Treatment of episodic hyperammonemia in children with inborn errors of urea synthesis. , 1984, The New England journal of medicine.

[11]  G. Dover.  Pharmacologic Manipulation of Fetal Hemoglobin , 1990, Annals of the New York Academy of Sciences.

[12]  S. Charache.  Hydroxyurea as treatment for sickle cell anemia. , 1991, Hematology/oncology clinics of North America.

[13]  J. Clegg,et al.  K562 human leukaemic cells synthesise embryonic haemoglobin in response to haemin , 1979, Nature.

[14]  V. L. Wilson,et al.  Increased sensitivity of nontumorigenic fibroblasts expressing ras or myc oncogenes to malignant transformation induced by 5-aza-2'-deoxycytidine. , 1991, Cancer research.

[15]  T. Ley,et al.  Hydroxyurea induction of hemoglobin F production in sickle cell disease: relationship between cytotoxicity and F cell production. , 1986, Blood.

[16]  A. Schechter,et al.  Inhibitors of cell division reversibly modify hemoglobin concentration in human erythroleukemia K562 cells. , 1981, Blood.

[17]  G. Dover,et al.  Treatment of sickle cell anemia with 5-azacytidine results in increased fetal hemoglobin production and is associated with nonrandom hypomethylation of DNA around the gamma-delta-beta-globin gene complex. , 1983, Proceedings of the National Academy of Sciences of the United States of America.

[18]  D. Nathan.  Pharmacologic Manipulation of Fetal Hemoglobin in the Hemoglobinopathies a , 1990, Annals of the New York Academy of Sciences.

[19]  D. Samid,et al.  Increased fetal hemoglobin in patients receiving sodium 4-phenylbutyrate. , 1992, The New England journal of medicine.

[20]  M. Reiss,et al.  Induction of tumor cell differentiation as a therapeutic approach: preclinical models for hematopoietic and solid neoplasms. , 1986, Cancer treatment reports.

[21]  R. Hoffman,et al.  Embryonic-fetal erythroid characteristics of a human leukemic cell line. , 1980, Proceedings of the National Academy of Sciences of the United States of America.

[22]  J. Adamson,et al.  Treatment of the anemia of progressive renal failure with recombinant human erythropoietin. , 1989, The New England journal of medicine.

[23]  G. Weber.  Biochemical strategy of cancer cells and the design of chemotherapy: G. H. A. Clowes Memorial Lecture. , 1983, Cancer research.

[24]  M A Medina,et al.  Glutamine and glucose as energy substrates for Ehrlich ascites tumour cells. , 1988, Biochemistry international.

[25]  M. James,et al.  The conjugation of phenylacetic acid in man, sub-human primates and some non-primate species , 1972, Proceedings of the Royal Society of London. Series B. Biological Sciences.

[26]  G. Rivard,et al.  Clinical trial on 5-aza-2'-deoxycytidine in patients with acute leukemia. , 1985, Pharmacology & therapeutics.